Real-time SEC alerts Start Free →
Profitelligence
Incyte Corporation
INCY HIGH Impact

Incyte Corporation

Incyte Appoints New CEO Following Retirement of Previous CEO

| 8-K |Healthcare

Summary

Incyte Corporation announced on June 26, 2025, that Hervé Hoppenot has retired as President and Chief Executive Officer, effective the same date. Julian C. Baker, Lead Independent Director, assumed the role of Chairman of the Board. William J. Meury has been appointed as the new President and Chief Executive Officer, effective June 26, 2025. Meury will also serve on the Board. The company entered into a transition agreement with Hoppenot, who will serve as a special advisor and a non-employee consultant for up to one year following his retirement. In connection with Meury's appointment, the company amended its 2024 Inducement Stock Incentive Plan to increase the number of authorized shares and adjusted the share count provisions.

Profitelligence Profitelligence Alerts

Get alerts for INCY

Be first to know when Incyte Corporation files with the SEC.

Set Up Alerts →

Filing Categories

CEO Resignation New CEO Appointed Exhibits Furnished

Exhibits (4)

Advertisement

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.

Exchange: NASDAQ Industry: Biotechnology Company Website →

Official SEC Documents

INCY
INCY Research
8Ks, insider trades, financials, technicals
SEC Alert Manager
Get alerts within 60 seconds of new filings

Advertisement